AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06045000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-DC-806
Description: Oral capsules
Study NCT05820997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
Study NCT05509595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
Study NCT06425926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIM-531
Description: GIM-531 administered orally daily
Study NCT06425926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Continued treatment with anti-PD-1 therapy
Study NCT05530070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
Study NCT05530070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients will receive standard of care and baseline dietary education.
Study NCT05530070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular risk-related parameters
Description: Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
Study NCT05872477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Topical
Description: There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
Study NCT05872477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
Study NCT05415124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoPill
Description: The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.
Study NCT05415124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy is performed as scheduled.
Study NCT06304324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
Study NCT06304324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1mg/kg Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
Study NCT06304324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05ug/kg Dexmedetomidine
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block
Study NCT06261216 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: * International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form
Study NCT05031780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Mitapivat tablets
Study NCT05031780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat-matching placebo
Description: Placebo to match 50 mg or 100 mg tablets
Study NCT05031780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat-matching placebo
Description: Placebo to match 100 mg tablets
Study NCT05873504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Oscillatory Index Device
Description: This device is commonly used to provide assistance with airway secretion clearance.
Study NCT05873504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Oscillatory Index Device
Description: This device is commonly used to provide assistance with airway secretion clearance.
Study NCT04680663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral Perfusion index
Description: Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
Study NCT04680663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum lactate level
Description: Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
Study NCT04781322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.
Study NCT04781322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Heavy drinking healthy volunteers
Study NCT06270173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)
Description: The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
Study NCT05539469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortodontika app
Description: parents will download and use Ortodontika smartphone application for all the duration of the study. It will be an aid during orthopedic treatment. During the activations, a notification will be set to remind the daily activation of RME. After the end of the activation protocol, parents will receive a notification every 2 weeks to instruct their children to proper oral hygiene maneuvers. Parents will have to show their children the videos for oral hygiene maintenance every 2 weeks until the end of the study.
Study NCT05539469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Verbal instructions
Description: verbal instructions will be given chairside to patients and parents regarding RME activation and its cleaning, together with instructions for daily oral hygiene manoeuvres.
Study NCT06638229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The StimaWELL 120MTRS system
Description: A standardized current (dynamic deep wave stimulation) was applied to all patients. Additionally, the mat, which reached a temperature of 40°C, provided heat therapy with electrical stimulation
Study NCT06308497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Treatment
Description: Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day Probiotic supplementation with daily assumption of Limosilactobacillus Reuteri Prodentis® tablet (PerioBalance, Gum®)
Study NCT06308497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day
Study NCT05899036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RapidPulseTM Aspiration System
Description: The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the cerebral vasculature using pulsatile aspiration. The system is comprised of a sterile one-time use 071 catheter, a sterile one-time use tubing set and a multiuse aspiration pump console.
Study NCT06300372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-TAPA plane block
Description: As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied bilaterally (60 ml in total).
Study NCT06300372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative pain management
Description: For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.
Study NCT06300372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain management
Description: For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.
Study NCT06382155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide Injection
Description: Experimental Drug Lyophilized powder for reconstitution
Study NCT06382155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Growth Hormone
Description: Commercial product containing somatotropin
Study NCT06382155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized powder for reconstitution
Study NCT06003127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation and measurement of related evoked potentials in the EEG.
Study NCT06016972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: QLS-111 ophthalmic solution, (0.015%)
Description: QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Study NCT06016972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: QLS-111 ophthalmic solution, (0.03%)
Description: QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Study NCT06016972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: QLS-111 ophthalmic solution, (0.075%)
Description: QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Study NCT06016972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QLS-111 ophthalmic vehicle solution
Description: Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Study NCT05790863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergometer cycling
Description: Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
Study NCT05790863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ergometer cycling
Description: Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
Study NCT06636383 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No investigational/study product will be administered in this DMP.
Study NCT05182801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: Blank
Study NCT05182801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Banana flower extract sachet
Description: Happy Angel Banana Flower Extract sachet
Study NCT05681364 — intervention group
Intervention type: OTHER
Intervention: metabonomics
Description: profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation
Study NCT06260917 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: position of urination
Description: effect of position on uroflowmetry parameters
Study NCT06629818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)
Description: qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12
Study NCT06629818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 400mg po qd for 1 year
Study NCT06629818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months
Study NCT05328362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CanCope
Description: Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
Study NCT05562297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Patients firstly receive sintilimab 200 mg (iv, 30 minutes) on day 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT05562297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 125 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT05562297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT05828680 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study NCT06407791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LymphaVibe
Description: The LymphaVibe is a newly-developed device that uses a vibratory sequence to gently move stagnant lymphatic fluid from the arm to the nearest group of functioning lymph nodes
Study NCT05314374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ileocolonic-release conjugated bile acid
Description: 1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days
Study NCT05314374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks exactly like the study drug, but it contains no active ingredient. 1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days.
Study NCT06298318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vodka
Description: BMI: if 18.5 ≤ BMI \< 24.0, individuals received 1.0 g/kg body weight of vodka; if 24.0 ≤ BMI ≤ 28.0, individuals received 0.8 g/kg body weight of vodka.
Study NCT06298318 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
Study NCT05996107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 400 mg daily with a possibly dose reduction to 200 mg daily if required
Study NCT05996107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative Radiation Therapy
Description: 50 Gy in 25 fractions or 42.56 Gy in 16 fraction +/- 10 Gy boost including comprehensive nodal
Study NCT04415372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.
Study NCT04415372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Testing
Description: A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.
Study NCT05341817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
Study NCT05341817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
Study NCT04855175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Bone Allograft (ClearFit)
Description: Patients in this arm will receive ClearFit (synthetic bone allograft)
Study NCT04855175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autograft
Description: Patients in this arm will use patient's own bone
Study NCT06292923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foralumab
Description: Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare.
Study NCT06292923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Foralumab placebo nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).
Study NCT05784246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab IV
Description: Administered IV
Study NCT05784246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab SC
Description: Administered SC
Study NCT06008730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06008730 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study NCT06008730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiology, Treatment Planning
Description: Undergo radiation treatment planning